Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 2/20 | 0.56 |
| ▸ | REN | P00797 | 10/20 | 0.55 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.47 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.47 |
| ▸ | RAMP3 | O60896 | 5/20 | 0.47 |
| ▸ | CALCR | P30988 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17226098 | 0.89 | REN (0.61) | PLK1RENCTSDPLK3PLK2 | |
| SCHEMBL7842935 | 0.89 | REN (0.65) | PLK1RENCTSDPLK3PLK2 | |
| SCHEMBL7849192 | 0.89 | REN (0.65) | PLK1RENCTSDPLK3PLK2 | |
| SCHEMBL7852891 | 0.89 | REN (0.65) | PLK1RENCTSDPLK3PLK2 | |
| SCHEMBL464254 | 0.87 | PLK1 (0.50) | PLK1RENCTSDAPLNRRAMP3 | |
| SCHEMBL464257 | 0.86 | PLK1 (0.49) | PLK1RENCTSDAPLNRRAMP3 | |
| SCHEMBL10087705 | 0.86 | PLK1 (0.48) | PLK1RENCTSDAPLNRRAMP3 | |
| SCHEMBL15729472 | 0.85 | REN (0.56) | PLK1RENCTSDPLK3PLK2 | |
| SCHEMBL13470161 | 0.84 | REN (0.56) | PLK1RENCTSD | |
| SCHEMBL22930164 | 0.83 | PLK1 (0.70) | PLK1RENPLK3PLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266565-B2 | Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2019-04-23 | — | — | US | disclosed |
| US-9175038-B2 | Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140142044-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | The United States of America, as represented by the Secretary, Department of Health & Human Servic (US) | 2014-05-22 | — | — | US | disclosed |
| US-20120065146-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142044-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PLK4, PLK3 | PLK1 1/4885REN 4534/4885CTSD 1655/4885 |
| US-20120065146-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PLK2, PLK4 | PLK1 1/4885REN 4353/4885CTSD 3127/4885 |
| US-10266565-B2 | Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use | PLK1, POLK, POLD3 | PLK1 1/4885REN 4204/4885CTSD 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.